• Je něco špatně v tomto záznamu ?

Novel germline JAK2R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon

J. Song, L. Lanikova, SJ. Kim, N. Papadopoulos, J. Meznarich, SN. Constantinescu, B. Parsegov, JF. Prchal, JT. Prchal

. 2024 ; 99 (7) : 1220-1229. [pub] 20240417

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013395

Grantová podpora
24-11730S Grantová Agentura České Republiky
LX22NPO5102 Next Generation EU
16/21-073 Ludwig Institute for Cancer Research
n°T.0043.21 Projet de recherche FNRS
MPN Research Foundation
Fonds De La Recherche Scientifique - FNRS
F 44/8/5 - MCF/UIG - 10955 Walloon excellence in life sciences and biotechnology
NU21/03/00338 Czech Health Research Council

Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2V617F or several others in exon 12. A 38-year-old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2R715T mutation. Computer modeling indicated gain-of-function JAK2 activity. The propositus and her mother had polyclonal myelopoiesis, ruling out another somatic mutation-derived clonal hematopoiesis. Some erythroid progenitors of all three generations grew without erythropoietin, a hallmark of PV. The in vitro reporter assay confirmed increased activity of the JAK2R715T kinase. Similar to PV, the JAK2R715T native cells have increased STAT5 phosphorylation, augmented transcripts of prothrombotic and inflammatory genes, and decreased KLF2 transcripts. The propositus was not controlled by hydroxyurea, and JAK2 inhibitors were not tolerated; however, Ropeginterferon-alfa-2b (Ropeg-IFN-α) induced a remission. Ropeg-IFN-α treatment also reduced JAK2 activity in the propositus, her mother and JAK2V617F PV subjects. We report dominantly inherited erythrocytosis secondary to a novel germline JAK2R715T gain-of-function mutation with many but not all comparable molecular features to JAK2V617F PV. We also document a previously unreported inhibitory mechanism of JAK2 signaling by Ropeg-IFN-α.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013395
003      
CZ-PrNML
005      
20240905133307.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27311 $2 doi
035    __
$a (PubMed)38629639
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Song, Jihyun $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000212690892
245    10
$a Novel germline JAK2R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon / $c J. Song, L. Lanikova, SJ. Kim, N. Papadopoulos, J. Meznarich, SN. Constantinescu, B. Parsegov, JF. Prchal, JT. Prchal
520    9_
$a Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2V617F or several others in exon 12. A 38-year-old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2R715T mutation. Computer modeling indicated gain-of-function JAK2 activity. The propositus and her mother had polyclonal myelopoiesis, ruling out another somatic mutation-derived clonal hematopoiesis. Some erythroid progenitors of all three generations grew without erythropoietin, a hallmark of PV. The in vitro reporter assay confirmed increased activity of the JAK2R715T kinase. Similar to PV, the JAK2R715T native cells have increased STAT5 phosphorylation, augmented transcripts of prothrombotic and inflammatory genes, and decreased KLF2 transcripts. The propositus was not controlled by hydroxyurea, and JAK2 inhibitors were not tolerated; however, Ropeginterferon-alfa-2b (Ropeg-IFN-α) induced a remission. Ropeg-IFN-α treatment also reduced JAK2 activity in the propositus, her mother and JAK2V617F PV subjects. We report dominantly inherited erythrocytosis secondary to a novel germline JAK2R715T gain-of-function mutation with many but not all comparable molecular features to JAK2V617F PV. We also document a previously unreported inhibitory mechanism of JAK2 signaling by Ropeg-IFN-α.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a aktivační mutace $7 D000073659
650    12
$a zárodečné mutace $7 D018095
650    _2
$a interferon alfa $x terapeutické užití $7 D016898
650    12
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a rodokmen $7 D010375
650    12
$a polycytemie $x genetika $x farmakoterapie $7 D011086
650    _2
$a polycythaemia vera $x genetika $x farmakoterapie $7 D011087
655    _2
$a časopisecké články $7 D016428
655    _2
$a kazuistiky $7 D002363
700    1_
$a Lanikova, Lucie $u Department of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000228458692
700    1_
$a Kim, Soo Jin $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000241741679
700    1_
$a Papadopoulos, Nicolas $u Ludwig Institute for Cancer Research, Brussels, Belgium $u de Duve Institute, Brussels, Belgium $1 https://orcid.org/000000017869862X
700    1_
$a Meznarich, Jessica $u Division of Hematology-Oncology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA $1 https://orcid.org/0000000172224351
700    1_
$a Constantinescu, Stefan N $u Ludwig Institute for Cancer Research, Brussels, Belgium $u de Duve Institute, Brussels, Belgium $u Nuffield Department of Medicine, Oxford University, Oxford, UK $u WELBIO Department, WEL Research Institute, Wavre, Belgium $1 https://orcid.org/0000000285992699
700    1_
$a Parsegov, Brynn $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0009000522260561
700    1_
$a Prchal, Jaroslav F $u McGill University Montreal, Quebec City, Quebec, Canada
700    1_
$a Prchal, Josef T $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000280192940
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 7 (2024), s. 1220-1229
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38629639 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133301 $b ABA008
999    __
$a ok $b bmc $g 2143294 $s 1225261
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 7 $d 1220-1229 $e 20240417 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a 24-11730S $p Grantová Agentura České Republiky
GRA    __
$a LX22NPO5102 $p Next Generation EU
GRA    __
$a 16/21-073 $p Ludwig Institute for Cancer Research
GRA    __
$a n°T.0043.21 $p Projet de recherche FNRS
GRA    __
$p MPN Research Foundation
GRA    __
$p Fonds De La Recherche Scientifique - FNRS
GRA    __
$a F 44/8/5 - MCF/UIG - 10955 $p Walloon excellence in life sciences and biotechnology
GRA    __
$a NU21/03/00338 $p Czech Health Research Council
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...